

February 14, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, "G" Block
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Regarding Outcome of the Board Meeting held on February 13, 2024, and duly intimated to Stock Exchange

Pursuant to outcome of Board meeting held on February 13, 2024 which was duly intimated to the stock exchange on February 13, 2024 and BSE Mail dated February 14, 2024 we would like to inform you that we have inadvertently missed to mention the conclusion timing of the Board Meeting.

Accordingly, as per the instructions received from BSE, we hereby re-submit the outcome of Board Meeting as mentioned below:

Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations"), we wish to inform you that the Board of Directors of Innova Captab Limited, at its meeting on February 13, 2024, inter-alia considered the following matter:

1. Approval of the Un-Audited (Standalone and Consolidated) Financial Results for the quarter and nine months ended December 31, 2023.

In terms of Regulation 33 of the Listing Regulations and pursuant to the approval of the Board of Directors of the Company, we are enclosing herewith copy of the following as **Annexure 1**:

- a. Un-Audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023;
- b. Limited Review Report on the said Un-Audited Financial Results (Standalone and Consolidated) received by the Statutory Auditors of the Company.

The Board Meeting commenced at 04:20 p.m. and concluded at 05.00 p.m.

Further we confirm that except timing of Board meeting all details remain unchanged.

This disclosure along with the enclosures shall be made available on the website of the Company viz. www.innovacaptab.com.

This is for your information and record.

Thanking you,

Yours faithfully,
For **Innova Captab Limited**

Neeharika Shukla
Company Secretary & Compliance Officer
Membership No.: A42724

B S R & Co. LLP

Chartered Accountants

Unit No. A505A
5th Floor, Elante Offices
Plot No. 178-178A, Industrial Area
Phase - 1, Chandigarh – 160002
Tel: +91 172 672 3400

Limited Review Report on unaudited standalone financial results of Innova Captab Limited for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Innova Captab Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Innova Captab Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 ("the Statement").

Attention is drawn to the fact that the figures for the corresponding quarter ended 31 December 2022 and the corresponding period from 1 April 2022 to 31 December 2022, as reported in these unaudited standalone financial results have been approved by the Company's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly standalone financial results has become mandatory with effect from quarter ended on or after 30 September 2023.

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Gaurav Mahajan

Partner

Membership No.: 507857

UDIN: 24507857BKFUPG2438

Panchkula
13 February 2024

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

INNOVA CAPTAB LIMITED

Regd. Office : 601, Proxima, Plot no.19, Sector J0 A, Vashi, Navi Mumbai, Maharashtra - 400 705,

CIN : U24246MH2005PLC150371, Website: www.innovacaptab.com, Email id : investors@innovacaptab.com, T : 91-22-25642095

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2023

(Rupees in millions, except for share data unless otherwise stated)

S.No.	Particulars	Quarter ended		Nine months ended		Year ended	
		31-Dec-2023	30-Sep-2023	31-Dec-2022	31-Dec-2023	31-Dec-2022	31-Mar-2023
		Unaudited	Unaudited	Unaudited (Refer Note 4)	Unaudited	Unaudited (Refer Note 4)	Audited
1	INCOME						
	a) Revenue from operations	2,364.60	2,117.34	2,282.75	6,668.27	6,421.10	8,586.73
	b) Other income	17.72	21.09	28.01	47.10	62.66	87.34
	Total Income (1)	2,382.32	2,138.43	2,310.76	6,715.37	6,483.76	8,674.07
2	EXPENSES						
	a) Cost of materials consumed	1,714.73	1,574.93	1,710.35	4,953.63	4,847.43	6,471.21
	b) Purchase of stock-in-trade	1.48	12.52	113.54	14.21	159.92	216.48
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	52.83	13.71	(43.68)	35.69	(22.54)	(14.80)
	d) Employee benefits expense	133.02	121.28	109.31	370.01	326.90	435.97
	e) Finance cost	38.13	52.04	53.33	134.71	133.25	183.00
	f) Depreciation and amortisation expense	29.70	28.10	24.71	84.70	78.18	106.56
	g) Other expenses	157.35	132.05	105.41	448.92	340.87	492.58
	Total Expenses (2)	2,127.24	1,934.63	2,072.97	6,041.87	5,864.01	7,891.00
3	Profit before Tax (1-2)	255.08	203.80	237.79	673.50	619.75	783.07
4	Tax expenses						
	- Current tax	66.12	57.48	69.99	182.99	163.77	188.61
	- Deferred tax	2.45	1.59	6.39	6.10	15.47	18.94
	Total tax expense (4)	68.57	59.07	76.38	189.09	179.24	207.55
5	Profit for the period / year (3-4)	186.51	144.73	161.41	484.41	440.51	575.52
6	Other Comprehensive Income (OCI)						
	A. (i) Items that will not be reclassified to Profit or Loss	0.48	0.10	2.09	4.25	2.09	(0.79)
	(ii) Income tax related to items that will not be reclassified to profit or loss	(0.12)	(0.03)	(0.13)	(1.07)	(0.53)	0.20
	B. (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive income / (loss) (net of tax)	0.36	0.07	1.96	3.18	1.56	(0.59)
7	Total Comprehensive income for the period / year (5+6)	186.87	144.80	163.37	487.59	442.07	574.93
8	Paid-up equity share capital (face value Rs. 10 per share)	572.25	480.00	480.00	572.25	480.00	480.00
9	Other equity						2,203.20
10	Basic and diluted earnings per share in Rs. (not annualised for the Quarters and Nine months)	3.26	3.02	3.36	8.47	9.18	11.99

See accompanying notes to the unaudited standalone financial results



Handwritten signature in blue ink.

Handwritten initials 'JS' in blue ink.

Notes :

- 1 The above unaudited standalone financial results as reviewed and recommended by the Audit Committee on 13 February 2024 and approved by the Board of Directors in their meeting held on 13 February 2024. The above unaudited standalone financial results have been subjected to limited review by the Statutory Auditors of the Company. The Statutory Auditors of the Company have expressed an unmodified review conclusion on the unaudited standalone financial results for the quarter and nine months ended 31 December 2023. The unmodified review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited (NSE). For more details on the unaudited standalone financial results, visit 'Investor Relations' section of our website at www.innovacaptab.com and 'Financial Results' in 'Corporates' section of www.nseindia.com and www.bseindia.com.
- 2 The above unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations, including relevant circulars issued by the SEBI from time to time.
- 3 The Company has only one reportable segment i.e. "Drugs and pharmaceutical products" as per Ind-AS 108 "Operating Segments" specified under section 133 of the Companies Act, 2013.
- 4 The figures for quarter and nine months 31 December 2022, as reported in these unaudited standalone financial results have been approved by the Company's Board of Directors, but have not been subjected to review by statutory auditor since the requirement of submission of quarterly standalone financial results is applicable on listing of equity shares of the Company, which was from quarter ended 30 September 2023.
- 5 During the quarter ended 31 December 2023:-
 - a) The Company has allotted 14,12,430 equity shares having face value of Rs. 10 each in the conversion ratio of 1:1 towards Compulsorily Convertible Preference Shares ("CCPS") on 01 December 2023 at a price of Rs. 448 per share.
 - b) The Company has allotted 6,69,642 Pre Initial Public Offer (IPO) equity shares having face value of Rs.10 each on 03 December 2023 at a price of Rs. 448 per share.
- 6 The Company has completed its IPO of 12,723,214 equity shares of face value Rs. 10 each at an issue price of Rs. 448 per share (including a share premium of Rs. 438 per share) and as a result the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 29 December 2023. The issue comprised of a fresh issue of 7,142,857 equity shares aggregating to Rs. 3,200.00 million and offer for sale of 5,580,357 equity shares by selling shareholders aggregating to Rs.2,500.00 million
The Company has estimated Rs. 478.39 million as IPO related expenses and allocated such expenses between the Company Rs. 268.91 million (of this amount, Rs 258.69 million has been adjusted to the security premium account) and selling shareholders Rs. 209.48 million in proportion to the equity shares allotted to the public as fresh issue by the Company and under offer for sale by selling shareholder respectively.

The Company has received an amount of Rs 2,931.09 million (net of IPO expenses of Rs.268.91 million) from proceeds out of fresh issue of equity shares. The utilisation of the net IPO proceeds is summarised below

(Rupees in million)				
Objectives as per Prospectus	Planned net proceeds as per prospectus	Actual net proceeds	Utilization upto 31 December 2023	Unutilized amount as on 31 December 2023*
Repayment and / prepayment, in part or in full, of certain outstanding loans of Company	1,444.00	1,444.00	-	1,444.00
Investment in subsidiary for repayment and / or prepayment in part or full outstanding loan availed by the subsidiary	236.00	236.00	-	236.00
Funding Company working capital requirements	720.00	720.00	-	720.00
General corporate purpose	531.09	531.09	-	531.09
Total Proceeds	2,931.09	2,931.09	-	2,931.09

* Out of the unutilized IPO proceeds as at 31 December 2023 amounting to Rs. 2,931.09 million, Rs.2,806.07 million are in monitoring account and Rs 125.02 million are in public issue account of the Company.

For and on behalf of the Board of Directors of
Innova Captab Limited



Vinay Kumar Lohariwala

Vinay Kumar Lohariwala
Managing Director
DIN:00144700

Gaurav Srivastava

Gaurav Srivastava
Chief Financial Officer,

Place: Panchkula
Date: 13 February 2024

Limited Review Report on unaudited consolidated financial results of Innova Captab Limited for the quarter ended 31 December 2023 and year to date results for the period from 01 April 2023 to 31 December 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Innova Captab Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Innova Captab Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2023 and year to date results for the period from 01 April 2023 to 31 December 2023 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Attention is drawn to the fact that the figures for the corresponding quarter ended 31 December 2022 and the corresponding period from 01 April 2022 to 31 December 2022, as reported in these unaudited consolidated financial results have been approved by the Parent's Board of Directors, but have not been subjected to review since the requirement of submission of quarterly consolidated financial results has become mandatory with effect from quarter ended on or after 30 September 2023.

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a. Innova Captab Limited - Parent Company
 - b. Univentis Medicare Limited - Subsidiary
 - c. Sharon Bio-Medicine Limited - Subsidiary (w.e.f. 30 June 2023)
 - d. Univentis Foundation - Subsidiary



Limited Review Report (*Continued*)

Innova Captab Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of two Subsidiaries included in the Statement, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs. 476.26 million and Rs. 957.44 million, total net profit after tax (before consolidation adjustments) of Rs. 27.86 million and Rs. 61.10 million and total comprehensive income (before consolidation adjustments) of Rs. 27.86 million and Rs. 61.97 million, for the quarter ended 31 December 2023 and for the period from 01 April 2023 to 31 December 2023 respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248WW-100022



Gaurav Mahajan

Partner

Panchkula

13 February 2024

Membership No.: 507857

UDIN: 24507857BKFUPH1772

INNOVA CAPTAB LIMITED

Regd. Office : 601, Proxima, Plot no.19, Sector 30 A, Vashi, Navi Mumbai, Maharashtra - 400 705,

CIN : U24246MH2005PLC150371, Website: www.innovacaptab.com, Email id : investors@innovacaptab.com, T : 91-22 25642095

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2023

(Rupees in millions, except for share data unless otherwise stated)

S.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-Dec-2023	30-Sep-2023	31-Dec-2022	31-Dec-2023	31-Dec-2022	31-Mar-2023
		Unaudited	Unaudited	Unaudited (Refer Note 4)	Unaudited	Unaudited (Refer Note 4)	Audited
1	INCOME						
	a) Revenue from operations	3,024.85	2,829.43	2,420.06	8,186.71	6,854.35	9,263.80
	b) Other income	23.40	33.39	27.21	68.04	65.76	91.98
	Total Income (1)	3,048.25	2,862.82	2,447.27	8,254.75	6,920.11	9,355.78
2	EXPENSES						
	a) Cost of materials consumed	1,909.41	1,787.30	1,635.52	5,360.69	4,847.41	6,466.06
	b) Purchase of stock-in-trade	60.03	93.80	205.78	235.23	297.58	447.91
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	51.37	33.45	(73.39)	4.85	(28.83)	1.65
	d) Employee benefits expense	256.32	242.46	136.90	647.65	408.87	547.97
	e) Finance cost	68.04	88.08	59.31	206.43	147.43	199.73
	f) Depreciation and amortisation expense	49.32	48.25	27.54	125.51	81.34	110.77
	g) Other expenses	301.75	267.64	173.16	774.55	460.83	663.74
	Total Expenses (2)	2,696.24	2,560.98	2,164.82	7,354.91	6,214.63	8,437.83
3	Profit before tax (1-2)	352.01	301.84	282.45	899.84	705.48	917.95
4	Tax expense						
	- Current tax	74.75	71.60	80.04	215.00	184.42	218.60
	- Deferred tax	26.00	1.19	6.62	28.60	14.05	19.81
	Total tax expense (4)	100.75	72.79	86.66	243.60	198.47	238.41
5	Profit for the period / year (3-4)	251.26	229.05	195.79	656.24	507.01	679.54
6	Other Comprehensive Income (OCI)						
	A. (i) Items that will not be reclassified to Profit or Loss	0.10	1.27	0.48	4.20	2.16	(0.72)
	(ii) Income tax related to items that will not be reclassified to profit or loss	(0.03)	(0.10)	(0.12)	(0.84)	(0.54)	0.18
	B. (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive (loss) / income (net of tax)	0.07	1.17	0.36	3.36	1.62	(0.54)
7	Total Comprehensive income for the period / year (5+6)	251.33	230.22	196.15	659.60	508.63	679.00
8	Paid-up equity share capital (face value Rs. 10 per share)	572.25	480.00	480.00	572.25	480.00	480.00
9	Other equity						2,285.06
10	Basic and diluted earnings per share in Rs. (not annualised for the Quarters and Nine months)	4.39	4.77	4.08	11.47	10.56	14.16

See accompanying notes to the unaudited consolidated financial results



Omney

CS

Notes :

- 1 The above unaudited consolidated financial results as reviewed and recommended by the Audit Committee on 13 February 2024 and approved by the Board of Directors in their meeting held on 13 February 2024. The above unaudited consolidated financial results have been subjected to limited review by the Statutory Auditors of the Company. The Statutory Auditors of the Company have expressed an unmodified review conclusion on the unaudited consolidated financial results for the quarter and nine months ended 31 December 2023. The unmodified review report of the Statutory Auditors is being filed with the BSE and National Stock Exchange Limited. For more details on the unaudited consolidated financial results, visit 'Investor Relations' section of our website at www.innovacaptab.com and 'Financial Results' in 'Corporates' section of www.nseindia.com and www.bseindia.com.
- 2 The above unaudited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations, including relevant circulars issued by the SEBI from time to time.
- 3 The Company has only one reportable segment i.e. "Drugs and pharmaceutical products" as per Ind-AS 108 "Operating Segments" specified under section 133 of the Companies Act, 2013.
- 4 The figures for quarter and nine months 31 December 2022, as reported in these unaudited consolidated financial results have been approved by the Company's Board of Directors, but have not been subjected to review by statutory auditor since the requirement of submission of quarterly standalone financial results is applicable on listing of equity shares of the Company, which was from quarter ended 30 September 2023.
- 5 During the quarter ended 31 December 2023:-
 - a) The Company has allotted 14,12,430 equity shares having face value of Rs. 10 each in the conversion ratio of 1:1 towards Compulsorily Convertible Preference Shares ("CCPS") on 01 December 2023 at a price of Rs. 448 per share.
 - b) The Company has allotted 6,69,642 Pre Initial Public Offer (IPO) equity shares having face value of Rs.10 each on 03 December 2023 at a price of Rs. 448 per share.
- 6 During the quarter ended 31 December 2023 the Company has completed its IPO of 12,723,214 equity shares of face value Rs. 10 each at an issue price of Rs. 448 per share (including a share premium of Rs. 438 per share) and as a result the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 29 December 2023. The issue comprised of a fresh issue of 7,142,857 equity shares aggregating to Rs. 3,200.00 million and offer for sale of 5,580,357 equity shares by selling shareholders aggregating to Rs. 2,500.00 million.

The Company has estimated Rs. 478.39 million as IPO related expenses and allocated such expenses between the Company Rs. 268.91 million (of this amount, Rs. 258.69 million has been adjusted to the security premium account) and selling shareholders Rs. 209.48 million in proportion to the equity shares allotted to the public as fresh issue by the Company and under offer for sale by selling shareholder respectively.

The Company has received an amount of Rs. 2,931.09 million (net of IPO expenses of Rs. 268.91 million) from proceeds out of fresh issue of equity shares. The utilisation of the net IPO proceeds is summarised below:

Objectives as per Prospectus	(Rupees in millions)			
	Planned net proceeds as per prospectus	Actual net proceeds	Utilization upto 31 December 2023	Unutilized amount as on 31 December 2023 *
Repayment and / prepayment, in part or in full, of certain outstanding loans of subsidiary Company	1,444.00	1,444.00	-	1,444.00
Investment in subsidiary for repayment and / or prepayment in part or full outstanding loan availed by the subsidiary	236.00	236.00	-	236.00
Funding Company working capital requirements	720.00	720.00	-	720.00
General corporate purpose	531.09	531.09	-	531.09
Total Proceeds	2,931.09	2,931.09	-	2,931.09

* Out of the unutilized IPO proceeds as at 31 December 2023 amounting to Rs. 2,931.09 millions, Rs. 2,806.07 million are in monitoring account and Rs. 125.02 million are in public issue account of the Company.

- 7 The Group acquired Sharon Bio-Medicine Limited as on 30 June 2023. Accordingly, the statement of unaudited consolidated financial results includes the financial results of the Sharon Bio-Medicine Limited from 1 July 2023 to 31 December 2023.



For and on behalf of the Board of Directors of
Innova Captab Limited

Vinay Kumar Lohariwala
Managing Director
DIN:00144700

Gaurav Srivastava
Chief Financial Officer

Place: Panchkula
Date: 13 February 2024